Low Pretreatment Acoustic Radiation Force Impulse Imaging (ARFI) Values Predict Sustained Virological Response in Antiviral Hepatitis C Virus (HCV) Therapy.
CONCLUSIONS Patients with chronic hepatitis C and pretreatment ARFI <1.5 m/s showed earlier virus elimination and better response to treatment.
PMID: 27690214 [PubMed - as supplied by publisher] (Source: Medical Science Monitor)
Source: Medical Science Monitor - October 2, 2016 Category: Research Tags: Med Sci Monit Source Type: research
Induction of S100 calcium-binding protein A2 expression in keratinocytes by telaprevir and trichloroethylene
Occupational exposure to trichloroethylene occasionally causes contact dermatitis, however, its molecular mechanism is still unknown. Telaprevir is a hepatitis C virus protease inhibitor and is widely used in combination with ribavirin and interferon α for patients with hepatits C virus infection. This combination therapy induces dermatologic adverse reactions at a much higher rate than an interferon monotherapy. To explore the common pathomechanism underlying the adverse skin reactions by trichloroethylene and telaprevir, we searched the gene which is induced both by trichloroethylene and telaprevir in normal human kerat...
Source: Journal of Dermatological Science - September 29, 2016 Category: Dermatology Authors: Manabu Yoshioka, Shun Ohmori, Daisuke Omoto, Sanehito Haruyama, Yu Sawada, Daisuke Nisio, Motonobu Nakamura Tags: P04-08[C12-01] Source Type: research
Diagnostics in hepatitis C: The end of response-guided therapy?
On-treatment hepatitis C virus (HCV) RNA has been used to predict response to interferon (IFN)-based therapy. The concept of response-guided treatment (RGT) was established to determine optimal treatment duration and to early identify patients not responding to futile therapies. RGT helped to improve sustained virologic response (SVR) rates and lower the rates of adverse effects. RGT was of particular importance for telaprevir- and boceprevir-based triple therapies. RGT strategies are dependent on highly sensitive and reproducible HCV RNA quantification. (Source: Journal of Hepatology)
Source: Journal of Hepatology - September 16, 2016 Category: Gastroenterology Authors: Benjamin Maasoumy, Johannes Vermehren Tags: Review Source Type: research
Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
CONCLUSIONS: LDV/SOF was cost-effective compared to most of the currently recommended treatments. Furthermore, LDV/SOF extends treatments to HCV-infected patients who are ineligible for interferon and RBV-based regimens. LDV/SOF thus has the potential to help reduce the burden of HCV in Japan.
PMID: 27609424 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - September 11, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan.
CONCLUSION: SOF combined with RBV was shown to be cost-effective in GT2 patients in Japan. Compared to PEGIFN + RBV, TVR + PEGIFN + RBV and no treatment SOF offers a more efficacious, shorter and better tolerated treatment option and extends treatment to reach HCV-infected patients who are ineligible for interferon-based regimens. Although adverse events were not included in the analyses, this would not make any changes to our conclusion.
PMID: 27608157 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - September 10, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
Telaprevir
(Source: Reactions Weekly)
Source: Reactions Weekly - August 31, 2016 Category: Drugs & Pharmacology Source Type: research
Ultra ‐deep sequencing analysis of resistance‐associated variants during retreatment with simeprevir‐based triple therapy after failure of telaprevir‐based triple therapy in patients with genotype 1 hepatitis C virus infection
ConclusionsIn this study, ultra‐deep sequencing analysis revealed that TVR and/or SMV‐resistant variants may have no influence on the effect of SMV‐based therapy after failure of TVR‐based therapy. Patients who discontinued treatment owing to adverse effects of TVR‐based therapy and relapsers to previous Peg‐IFN/RBV therapy would be good candidates for retreatment with SMV‐based therapy. (Source: Hepatology Research)
Source: Hepatology Research - August 31, 2016 Category: Internal Medicine Authors: Naoki Morishita, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Yuki Tahata, Ryoko Yamada, Takayuki Yakushijin, Atsushi Hosui, Sadaharu Iio, Akira Yamada, Hideki Hagiwara, Eiji Mita, Yukinori Yamada, Toshifumi Ito, Masami Inada, Kazuhiro Katayama, Iwao Yabuuc Tags: Original Article Source Type: research
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.
CONCLUSION: In everyday practice, triple therapy is safe but has moderate efficacy, especially for patients over 65 years of age, with advanced fibrosis, non-responders to peginterferon + ribavirin.
PMID: 27574549 [PubMed] (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - August 31, 2016 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions
Abstract Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued. Simeprevir is a second-wave PI incorporated into the Brazilian hepatitis C treatment protocol. Drug resistance plays a key role in patients' treatment regimen. Here, we developed a simple phenotypic assay to evaluate the impact of resistance mutations in HCV NS3 protease to PIs, using a protein expression vector containing wild type NS3 protease domain and NS4A co-factor. We analyzed the impact of...
Source: Genetics and Molecular Biology - August 30, 2016 Category: Genetics & Stem Cells Source Type: research
Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study.
CONCLUSIONS: CHC-related MRU increases substantially with disease severity. These real-world MRU data for GT1 CHC will be valuable in assessing the impact of new hepatitis C treatments.
PMID: 27552282 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - August 25, 2016 Category: Health Management Tags: J Med Econ Source Type: research
7th Drug hypersensitivity meeting: part two
Table of contentsPoster walk 11: miscellaneous drug hypersensitivity 2 (P92 –P94, P96–P101)P92 16 years of experience with proton pump inhibitors (PPIs)Javier Dionicio Elera, Cosmin Boteanu, Maria Aranzazu Jimenez Blanco, Rosario Gonzalez-Mendiola, Irene Carrasco Garc ía, Antonio Alvarez, Jose Julio Laguna MartinezP93 Allergy evaluation of quinolone induced adverse reactionsJaume Mart í Garrido, Carla Torán Barona, Carolina Perales Chorda, Ramón López Salgueiro, Miguel Díaz Palacios, Dolores Hernández Fernández De RojasP94 Bupropion-induced acute urticaria and angioedema, a case reportEmre Ali Acar, Ayse Akta...
Source: Clinical and Translational Allergy - August 24, 2016 Category: Allergy & Immunology Source Type: research
Exosomal MicroRNAs Derived From Umbilical Mesenchymal Stem Cells Inhibit Hepatitis C Virus Infection
Hepatitis C virus (HCV) is a significant global public health problem, causing more than 350,000 deaths every year. Although the development of direct-acting antivirals has improved the sustained virological response rate in HCV patients, novel anti-HCV agents with higher efficacy as well as better tolerance and cheaper production costs are still urgently needed. Cell-based therapy, especially its unique and strong paracrine ability to transfer information to other cells via extracellular vesicles such as exosomes, has become one of the most popular therapeutic methods in recent years. In our study, exosomes secreted from ...
Source: Stem Cells Translational Medicine - August 23, 2016 Category: Stem Cells Authors: Qian, X., Xu, C., Fang, S., Zhao, P., Wang, Y., Liu, H., Yuan, W., Qi, Z. Tags: Cord Blood Stem Cells, Tissue-Specific Progenitor and Stem Cells Source Type: research
Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection
The aim of this study was to assess the rate of development of hepatocellular carcinoma (HCC) in patients who achieved sustained virologic response (SVR) by direct antiviral agents (DAA). We retrospectively evaluated patients who achieved SVR by oral DAA interferon‐free regimens (n = 77) (daclatasvir/asunaprevir [n = 67], ombitasvir/paritaprevir/ritonavir [n = 9], and telaprevir [n = 1]) and by pegylated‐interferon plus ribavirin (Peg‐IFN/RBV, n = 528). In all patients, the background was chronic hepatitis or cirrhosis caused by HCV genotype 1b. During a median follow‐up period of 4.0 years, two...
Source: Journal of Medical Virology - August 22, 2016 Category: Virology Authors: Masahiro Kobayashi, Fumitaka Suzuki, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada Tags: Research Article Source Type: research
Sustained virologic response by direct anti ‐viral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection
This article is protected by copyright. All rights reserved (Source: Journal of Medical Virology)
Source: Journal of Medical Virology - August 16, 2016 Category: Virology Authors: Masahiro Kobayashi, Fumitaka Suzuki, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada Tags: Research Article Source Type: research
Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy.
CONCLUSIONS: Determination of serum IP-10 levels before treatment could be useful for predicting favorable virologic response to TVR-based triple therapy, especially in patients with IL28B non-TT genotype.
PMID: 27541605 [PubMed - as supplied by publisher] (Source: Cytokine)
Source: Cytokine - August 15, 2016 Category: Molecular Biology Authors: Yamagiwa Y, Asano M, Kawasaki Y, Korenaga M, Murata K, Kanto T, Mizokami M, Masaki N Tags: Cytokine Source Type: research
